Back to the main directory
Company Analysis / Equity
- Initiating Coverage of TransUnion With a Wide Moat Rating by Morningstar
- Emera's mostly regulated business mix drives capital growth opportunities. by Morningstar
- Smart Sand's Shares Drop on 1Q Results, but Our FVE Is Unchanged by Morningstar
- Weekly Market Wrap - 11 May 2018 by Vetiva Capital Management
- Tough Macro Equipment Conditions Continue for Ritchie in 1Q by Morningstar
- We’re Slightly Lowering CRH’s FVE After Re-Evaluating Several Assumptions by Morningstar
- We’re Slightly Lowering CRH’s FVE After Re-Evaluating Several Assumptions by Morningstar
- Power Gets a Pop From Sagard in 1Q by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- As Shares Fall, Thomson Reuters' Buyback Creates Value by Morningstar
- As Shares Fall, Thomson Reuters' Buyback Creates Value by Morningstar
- Fortis Management Continues to Identify Incremental Growth Opportunities by Morningstar
- Emera Energy and Florida Drive Solid 1Q Results by Morningstar
- AKD STOCK SMART, May 11, 2018 by AKD Securities Limited
- TDK Expects Robust Revenue Growth on Passive Components, Sensors, and Batteries; Shares Undervalued by Morningstar
- Strong Start to the Year for Pilgrim’s Pride as Its Strategy Delivers Benefits; Shares Attractive by Morningstar
- Tough Macro Equipment Conditions Continue for Ritchie in 1Q by Morningstar
- Raising Our BMW FVE to EUR 117 From EUR 110; Initiating ADR Coverage With $46 FVE by Morningstar
- Growing global demand for BMW premium-priced products supports solid economic profit. by Morningstar
- Lundbeck's Robust 1Q Results Overshadowed by the Storms Ahead; Shares Overvalued by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- Trump’s Drug Plan Looks to Modestly Lower Drug Prices, Keeping Big Pharma and Biotech Moats Intact by Morningstar
- The More Things Change the More They Stay The Same: Takeaways From Teleflex's Investor Day by Morningstar
- Sprint agrees to be acquired by T-Mobile US; the combined company should compete better by Morningstar
- National Bank of Canada's Excellent 1Q Results Support Our Positive View by Morningstar
- Mammoth Resources Corp. (TSXV: MTH) – Encouraging Drill Results by Fundamental Research